Key result
AF catheter ablation linked to ~14% lower risk of unplanned readmissions and death.
Why the study?
Data on long-term outcomes of catheter ablation for AF outside of clinical trial settings are sparse.
Does catheter ablation reduce unplanned heart failure, AF, stroke-related readmissions, and death at 1 year in patients admitted for atrial fibrillation?
Observational (n=93,759)
Yes
Does catheter ablation reduce unplanned heart failure, AF, stroke-related readmissions, and death at 1 year in patients admitted for atrial fibrillation?
Catheter ablation for atrial fibrillation is associated with a significantly lower risk of AF and stroke-related readmissions compared to medical management, with the greatest benefit seen in younger males with fewer comorbidities.
Answers are grounded in this paper and cite their sources.
May support ablation to lower readmissions in selected AF patients; leaves open randomized confirmation.
BACKGROUND: Data on long-term outcomes of catheter ablation (CA) for atrial fibrillation (AF) in outside of clinical trials settings are sparse. OBJECTIVE: We aimed to assess outcomes and readmissions at 1 year following admission for CA for AF. METHODS: Utilizing the Nationwide Readmissions Database (2016-2018), we identified patients with CA among all patients with a primary admission diagnosis of AF, and a control group by propensity score match adjusted for age, sex, comorbidities, CHA₂DS₂-VASc scores, and the hospital characteristics. The primary outcome was a composite of unplanned heart failure (HF), AF and stroke-related readmissions, and death at 1 year, and secondary outcomes were hospital outcomes and all-cause readmission rates. RESULTS: The study cohort consisted of 29,771 patients undergoing CA and 63,988 controls. Patients undergoing CA were younger with lower CHA₂DS₂-VASc scores and less comorbidities. Over a follow-up of 170 ±1.1 days, the primary outcome occurred in 5.2% in CA group and 6.0% of controls (hazard ratio [HR] and 95% confidence interval [CI]: 0.86 [0.76-0.94], p = .002). CA affected AF and stroke related readmission, but showed no effect on HF and mortality outcome. Male sex (HR: 0.83 [0.74-0.94], p = .03), younger age (HR: 0.71 [0.61-0.83], p < .001], and lower CHA₂DS₂-VASc scores (HR: 0.68 [0.55-0.84], p < .001) were associated with lower risk of primary outcome with CA. CONCLUSION: In this study, CA for AF was associated with significantly lower AF and stroke-related admissions, but not to HF or all-cause readmission. Better outcomes were seen among males, younger patients, and in patients with less comorbidities and low CHA₂DS₂-VASc scores.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2022) conducted an observational in Atrial fibrillation (n=93,759). Catheter ablation vs. Propensity score matched controls was evaluated on Composite of unplanned heart failure (HF), AF and stroke-related readmissions, and death at 1 year (HR 0.86, 95% CI 0.76-0.94, p=0.002). Catheter ablation for atrial fibrillation was associated with a lower risk of unplanned heart failure, AF, stroke-related readmissions, and death.
Synapse has enriched 10 related papers. Consider them for comparative context: